Skip to main content

Table 4 Immunophenotyping results in % (spleen) of Acanthamoeba spp.-infected immunosuppressed mice and control mice with low immunity

From: Changes in the immune system in experimental acanthamoebiasis in immunocompetent and immunosuppressed hosts

Parameter/group

  

Group AS

(n = 10)

Group CS

(n = 6)

Mann-Whitney U-test

CD3+/CD4+ (T lymphocytes) (%)

8 dpi

AM ± SD

22.67 ± 0.13

24.47 ± 0.09

U = 16, P = 0.53

Median

22.87

25.57

Range

18.62–26.69

21.51–26.73

16 dpi

AM ± SD

28.87 ± 0.05

27.51 ± 0.20

U = 15, P = 0.09

Median

25.09

25.78

Range

23.11–26.19

22.27–36.82

24 dpi

AM ± SD

25.17 ± 0.43

16.68 ± 0.18

U = 21, P = 0.05

Median

22.17

17.35

Range

14.67–43.74

12.04–20.34

CD3+/CD8+ (%)

8 dpi

AM ± SD

5.25 ± 0.14

6.16 ± 0.37

U = 14, P = 0.83

Median

5.21

6.03

Range

4.44–6.28

4.23–9.89

16 dpi

AM ± SD

7.40 ± 0.05

4.55 ± 0.24

U = 25, P = 0.01

Median

7.51

4.19

Range

6.83–7.94

3.39–6.36

24 dpi

AM ± SD

4.23 ± 0.60

4.10 ± 0.17

U = 19, P = 0.21

Median

5.54

3.83

Range

0.05–7.45

3.35–5.16

CD3+/CD4+/CD8+ (DP %)

8 dpi

AM ± SD

1.13 ± 0.19

1.82 ± 0.29

U = 21, P = 0.09

Median

1.18

1.87

Range

0.83–1.35

0.96–2.36

16 dpi

AM ± SD

1.52 ± 0.24

1.61 ± 0.38

U = 13, P = 0.99

Median

1.66

1.61

Range

0.98–1.94

1.17–2.6

24 dpi

AM ± SD

2.71 ± 0.89

1.32 ± 0.35

U = 19, P = 0.03

Median

1.63

1.07

Range

1.1–7.47

0.96–2.03

CD3+/CD4-/CD8- (DN %)

8 dpi

AM ± SD

0.12 ± 0.21

0.21 ± 0.18

U = 24, P = 0.02

Median

0.12

0.23

Range

0.1–0.16

0.16–0.24

16 dpi

AM ± SD

0.14 ± 0.10

0.09 ± 0.65

U = 20, P = 0.14

Median

0.14

0.09

Range

0.11–0.17

0.03–0.18

24 dpi

AM ± SD

0.16 ± 0.59

0.11 ± 0.26

U = 19, P = 0.15

Median

0.22

0.11

Range

0.004–0.24

0.07–0.13

  1. Abbreviations: Group A, immunocompetent infected group; Group C, immunocompetent control group; Group AS immunosuppressed infected group; Group CS, immunosuppressed non-infected group; AM, arithmetic mean; SD, standard deviation DP, CD3+/CD4+/CD8+ double-positive T cells; DN, CD3+CD4−CD8− double-positive T cells